RxDoctor Payments Data

Shreya Shah, MD

Neurology · Carlsbad, CANPI 1609360114

Payments from drug & device makers

$23,427in general payments, 2019–2025

Across 122 payments — averaging $192.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$20K
  • AbbVie$982
  • UCB, Inc.$295
  • Lilly USA, LLC$283
  • Neurocrine Biosciences, Inc.$263
  • Amneal Pharmaceuticals LLC$194
  • plus $1K from 16 others

What the payments were for

  • Grants$20,00085%
  • Travel & lodging$40%
  • Food & beverage$3,42315%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$23,427 in reported general payments places this provider in the 80th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$31,044
Medicare patients
125
Services billed
474

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate14$72,720
RytaryCarbidopa/Levodopa69$60,411
GocovriAmantadine Hcl18$59,830
Rasagiline Mesylate86$22,668
Carbidopa-LevodopaCarbidopa/Levodopa236$8,979
Carbidopa-Levodopa ErCarbidopa/Levodopa173$8,918
Carbidopa12$8,873
Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone29$6,671
Selegiline Hcl80$6,628
Entacapone20$4,093
RivastigmineRivastigmine Tartrate28$2,325
AmantadineAmantadine Hcl36$2,195
Donepezil Hcl104$1,680
Primidone19$1,047
Modafinil21$974

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Amneal Pharmaceuticals LLCRytary$194$60,41169 claims
MDD US Operations, LLCGocovri$32$59,83018 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,996 neurology providers in California.

Other neurology in Carlsbad

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →